Oracle Runs

Oracle findings and outcome history for A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (NCT06682806).

Runs

Findings

Latest Run

Apr 6, 2026, 2:57 PM

All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed95% confidenceGrok 4.20 (xAI)

Will the results be positive?

Phase 2 trial terminated early by sponsor decision after enrolling 6 patients (last update 2026-02-02). No public readout of results posted on ClinicalTrials.gov or sponsor releases. Strategic pause of SMARCA2 program (Nov 2025) due to data review and resource allocation, but no explicit framing of combo trial data as positive/negative. Evidence incomplete, no clear trial-specific interpretation.

Found Apr 6, 2026, 2:57 PMReviewed Apr 6, 2026, 3:00 PM

ClinicalTrialsclinicaltrials.govFeb 2, 2026, 12:00 AM

NCT06682806 Study Record

Status: Terminated (Sponsor decision). Enrolled: 6 patients. No results posted. Primary completion: 2026-01-23. Terminated early.

Sponsorinvestors.preludetx.comNov 4, 2025, 12:00 AM

Prelude Therapeutics Strategic Business Update

Pausing clinical development of SMARCA2 degrader program after review of clinical data to date and assessment of capital/resources vs other programs.

Web Searchtrialchangelog.comFeb 2, 2026, 12:00 AM

Trial Changelog Terminated Trials

NCT06682806 terminated 2026-02-02 by PRLD, reason: Sponsor decision.

NO_DECISIONDismissed80% confidenceGrok 4.20 (xAI)

Will the results be positive?

Trial terminated by sponsor decision before primary completion (enrolled ~6 patients). No efficacy results, readouts, or public statements frame this exact Phase 2 combo trial as positive or negative. Phase 1 monotherapy showed initial activity but led to program pause due to underwhelming data; combo trial has none.

Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:20 PM

Web Searchclinicaltrials.govApr 5, 2026, 3:37 PM

NCT06682806 on ClinicalTrials.gov

Terminated. Sponsor decision. Phase 2 study of PRT3789 + pembrolizumab in SMARCA4-mutated solid tumors. Primary endpoints: safety/tolerability (DLTs, AEs).

Web Searchinvestors.preludetx.comAug 14, 2025, 12:00 AM

Prelude Q2 2025 Financial Results

Pause further development of PRT3789 after Phase 1. Initial proof of concept but underwhelming; focus on oral backup. No mention of combo Phase 2 results.

Web Searchfiercebiotech.comAug 14, 2025, 12:00 AM

Fierce Biotech: Prelude calls it curtains on lead SMARCA2 asset

Pausing PRT3789 after underwhelming Phase 1 data. Decision after Phase 1 dose escalation; no efficacy data cited for the terminated Phase 2 combo trial.

NO_DECISIONDismissed80% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov lists this study as terminated but without posted results, so there is no clear public trial-specific basis yet to call the readout positive or negative.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM

ClinicalTrialsclinicaltrials.govFeb 2, 2026, 12:00 AM

Study Details | NCT06682806 | ClinicalTrials.gov

ClinicalTrials.gov lists terminated; primary completion 2026-01-23; hasResults=false on the latest posted update.

NO_DECISIONDismissed88% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No clear trial-specific efficacy readout was found for this Phase 2 study. The registry shows NCT06682806 was terminated, and Prelude later said it paused further PRT3789 development based on overall data/resource considerations, but neither source clearly frames this exact trial as a positive or negative Phase 2 result.

Found Apr 1, 2026, 6:39 PMReviewed Apr 1, 2026, 6:46 PM

ClinicalTrialsclinicaltrials.gov

Study Details | NCT06682806 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

ClinicalTrials.gov lists NCT06682806 as Terminated. The public record describes the Phase 2 combination study but does not provide a clear efficacy readout framing the exact trial as positive or negative.

Sponsorinvestors.preludetx.comAug 14, 2025, 12:00 AM

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Prelude said it decided to pause further development of PRT3789, citing considerations including target coverage and capital needs. It referenced Phase 1 completion and future data, not a clear positive/negative readout for NCT06682806.

Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.